Related references
Note: Only part of the references are listed.Ru(II) containing photosensitizers for photodynamic therapy: A critique on reporting and an attempt to compare efficacy
Manjunatha Ankathatti Munegowda et al.
COORDINATION CHEMISTRY REVIEWS (2022)
Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies
Yi Zhang et al.
CANCERS (2022)
Is antitumor Pt(IV) complex containing two axial lonidamine ligands a true dual- or multi-action prodrug?
Jana Kasparkova et al.
METALLOMICS (2022)
Ru(II) containing photosensitizers for photodynamic therapy: A critique on reporting and an attempt to compare efficacy
Manjunatha Ankathatti Munegowda et al.
COORDINATION CHEMISTRY REVIEWS (2022)
Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD-100/KP1339 in the Endoplasmic Reticulum
Benjamin Neuditschko et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Recent Approaches towards the Development of Ru(ii) Polypyridyl Complexes for Anticancer Photodynamic Therapy
Albert Gandioso et al.
CHIMIA (2021)
Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands
William D. J. Tremlett et al.
COORDINATION CHEMISTRY REVIEWS (2021)
Ru(III) Complexes with Lonidamine-Modified Ligands
Ilya A. Shutkov et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ruthenium(III) Complexes of NAMI-A Type with Ligands Based on Lonidamine and Bexarotene as Antiproliferative Agents
I. A. Shutkov et al.
RUSSIAN JOURNAL OF INORGANIC CHEMISTRY (2021)
Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer
Suzanne Bakewell et al.
CANCERS (2020)
The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment
Yaxin Huang et al.
CANCERS (2020)
Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update
Junmin Zhang et al.
MEDICINAL RESEARCH REVIEWS (2019)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio et al.
MOLECULES (2019)
Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis
Gang Cheng et al.
NATURE COMMUNICATIONS (2019)
Antiproliferative activity of Pt(IV) complexes with lonidamine and bexarotene ligands attached via succinate-ethylenediamine linker
Y. N. Okulova et al.
INORGANICA CHIMICA ACTA (2019)
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G. Kenny et al.
CHEMICAL REVIEWS (2019)
Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
James P. C. Coverdale et al.
INORGANICS (2019)
Ru(II) Polypyridyl Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging
Ao Li et al.
ACCOUNTS OF CHEMICAL RESEARCH (2018)
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions
Alberta Bergamo et al.
COORDINATION CHEMISTRY REVIEWS (2018)
Enhancing the Cytotoxic Activity of Anticancer PtIV Complexes by Introduction of Lonidamine as an Axial Ligand
Yulia N. Nosova et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
Enzo Alessio
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
Thioredoxin reductase inhibitors: a patent review
Baoxin Zhang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Inhibition of the α-carbonic anhydrase from Vibrio cholerae with amides and sulfonamides incorporating imidazole moieties
Daniela De Vita et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2017)
Cytotoxic platinum coordination compounds. DNA binding agents
Viktor Brabec et al.
COORDINATION CHEMISTRY REVIEWS (2017)
Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine
Yangzom D. Bhutia et al.
BIOCHEMICAL JOURNAL (2016)
Mechanism of antineoplastic activity of lonidamine
Kavindra Nath et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Timothy C. Johnstone et al.
CHEMICAL REVIEWS (2016)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
Howard A. Burris et al.
ESMO OPEN (2016)
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure
M. Vadori et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2015)
Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process
L. Brescacin et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2015)
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Suzanne Leijen et al.
INVESTIGATIONAL NEW DRUGS (2015)
Opening the lid on piano-stool complexes: An account of ruthenium(II)-arene complexes with medicinal applications
Alexey A. Nazarov et al.
JOURNAL OF ORGANOMETALLIC CHEMISTRY (2014)
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity
Zenita Adhireksan et al.
NATURE COMMUNICATIONS (2014)
DMSO-Mediated Ligand Dissociation: Renaissance for Biological Activity of N-Heterocyclic-[Ru(η6-arene)Cl2] Drug Candidates
Malay Patra et al.
CHEMISTRY-A EUROPEAN JOURNAL (2013)
Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death
Alexey A. Nazarov et al.
DALTON TRANSACTIONS (2013)
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Patrycja Nowak-Sliwinska et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics
Ryan C. Todd et al.
CHEMISTRY & BIOLOGY (2010)
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study
Frederike Lentz et al.
ANTI-CANCER DRUGS (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger et al.
CHEMISTRY & BIODIVERSITY (2008)
From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
Influence of hydrogen-bonding substituents on the cytotoxicity of RAPTA compounds
C Scolaro et al.
ORGANOMETALLICS (2006)
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes
C Scolaro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175
RL Hayward et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: Novel recognition mechanisms
HM Chen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design
A Berruti et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
[Ru(eta(6)-p-cymene)Cl-2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells
CS Allardyce et al.
CHEMICAL COMMUNICATIONS (2001)
Share Paper
